139 related articles for article (PubMed ID: 17601341)
41. Soluble HLA class I and class II antigens in patients with multiple sclerosis.
Ott M; Seidl C; Westhoff U; Stecker K; Seifried E; Fischer PA; Grosse-Wilde H
Tissue Antigens; 1998 Mar; 51(3):301-4. PubMed ID: 9550332
[TBL] [Abstract][Full Text] [Related]
42. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.
Caon C; Din M; Ching W; Tselis A; Lisak R; Khan O
Eur J Neurol; 2006 May; 13(5):471-4. PubMed ID: 16722971
[TBL] [Abstract][Full Text] [Related]
43. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J;
Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043
[TBL] [Abstract][Full Text] [Related]
44. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis.
Losy J; Michałowska-Wender G
Acta Neurol Scand; 2002 Jul; 106(1):44-6. PubMed ID: 12067328
[TBL] [Abstract][Full Text] [Related]
45. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
[TBL] [Abstract][Full Text] [Related]
46. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
47. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
[TBL] [Abstract][Full Text] [Related]
48. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
Koch-Henriksen N; Sørensen PS
Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
[TBL] [Abstract][Full Text] [Related]
49. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
[TBL] [Abstract][Full Text] [Related]
50. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
[TBL] [Abstract][Full Text] [Related]
52. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
53. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
Løken-Amsrud KI; Holmøy T; Bakke SJ; Beiske AG; Bjerve KS; Bjørnarå BT; Hovdal H; Lilleås F; Midgard R; Pedersen T; Benth JS; Sandvik L; Torkildsen O; Wergeland S; Myhr KM
Neurology; 2012 Jul; 79(3):267-73. PubMed ID: 22700809
[TBL] [Abstract][Full Text] [Related]
54. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
[TBL] [Abstract][Full Text] [Related]
55. Soluble HLA in human body fluids.
Aultman D; Adamashvili I; Yaturu K; Langford M; Gelder F; Gautreaux M; Ghali GE; McDonald J
Hum Immunol; 1999 Mar; 60(3):239-44. PubMed ID: 10321960
[TBL] [Abstract][Full Text] [Related]
56. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
57. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
[TBL] [Abstract][Full Text] [Related]
58. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
59. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
[TBL] [Abstract][Full Text] [Related]
60. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
